Design Therapeutics, Inc. (DSGN) research
Design Therapeutics, Inc.- Sector
- Biotechnology
- Last price
- $12.55
- As of
Design Therapeutics, Inc. (DSGN): 6 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-08-03.
As of . Source: SEC EDGAR filings for DSGN. Method and limitations.
Share the DSGN intelligence card
See DSGN live in the terminal
Track DSGN's insider trades, 13F flows, options positioning, and cross asset confluence as they update, on one live board. Free account.
Open the live DSGN terminal, freeActive signals for DSGN
- highINSTITUTIONAL_EXIT
CITADEL ADVISORS LLC cut 82% of DSGN (2026Q2)
- highINSTITUTIONAL_EXIT
CITADEL ADVISORS LLC cut 97% of DSGN (2026Q2)
- highINSTITUTIONAL_EXIT
D. E. Shaw & Co., Inc. cut 58% of DSGN (2026Q2)
- highINSTITUTIONAL_SURGE
TWO SIGMA INVESTMENTS, LP added +102% to DSGN (2026Q2)
- highINSTITUTIONAL_EXIT
CITADEL ADVISORS LLC cut 97% of DSGN (2026Q2)
FREE, NO ACCOUNT
Every signal on DSGN, as it fires
You are seeing 5 of 18 signals recorded on DSGN since 2026-05-26.
The five above all landed on 2026-09-06. The other 13 were recorded on 3 other days. 14 of the 18 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in DSGN (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| Point72 Asset Management, L.P.CUSIP 25056L103 · 2026Q2 | $34.2M | 0.04% | , |
| RENAISSANCE TECHNOLOGIES LLCCUSIP 25056L103 · 2026Q2 | $5.6M | 0.01% | , |
| D. E. Shaw & Co., Inc.CUSIP 25056L103 · 2026Q2 | $2.8M | 0.00% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP 25056L103 · 2026Q2 | $2.1M | 0.00% | , |
| CITADEL ADVISORS LLCCUSIP 25056L103 · 2026Q2 | $1.2M | 0.00% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 25056L103 · 2026Q2 | $476K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, DSGN
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
DSGN against its peers
DSGN's return on equity of -32.8% ranks in the 74th percentile of 20 Biotechnology sub-industry peers, fiscal period ending 2025-12-31.
| Metric | DSGN | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 0.0 USD | 58.6M USD | 5 | 10 |
| Operating margin | n/a | -229.1% | n/a | 10 |
| Net margin | n/a | -201.2% | n/a | 10 |
| Return on equity | -32.8% | -41.6% | 74 | 20 |
Peers (21): SANA, AVTX, CADL, SGP, LXRX, SLDB, IMMX, CLYM, TBPH, ARDX, GERN, JANX, RIGL, OLMA, WVE, ABUS, FDMT, KURA, ACHV, SVRA, MLTX. Left out: IVA (period gap), ANL (period gap), HELP (period gap), ATTO (no annual filing). Fiscal period ending 2025-12-31. Every figure is one full fiscal year read from one annual filing (DSGN: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
See more DSGN signals as they fire
Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to DSGNand get the insider, 13F, options, and confluence read in one view.